Investment Analysts’ Weekly Ratings Updates for Beta Bionics (BBNX)

Several analysts have recently updated their ratings and price targets for Beta Bionics (NASDAQ: BBNX):

• 10/12/2026 – Beta Bionics is now covered by Jefferies Financial Group. They set a “buy” rating and a $30.00 price target on the stock.
• 10/12/2026 – Beta Bionics is now covered by Jefferies Financial Group. They set a “buy” rating and a $30.00 price target on the stock.
• 10/6/2026 – Beta Bionics is now covered by Barclays. They set an “overweight” rating and a $30.00 price target on the stock.
• 10/6/2026 – Beta Bionics was upgraded by Barclays to “strong-buy”.
• 9/24/2026 – Beta Bionics had its price target raised by Truist Financial from $23.00 to $28.00. They now have a “buy” rating on the stock.
• 9/23/2026 – Beta Bionics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $28.00 price target on the stock.
• 9/23/2026 – Beta Bionics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $28.00 price target on the stock.
• 9/19/2026 – Beta Bionics was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/15/2026 – Beta Bionics had its “buy” rating reaffirmed by Truist Financial. They now have a $23.00 price target on the stock, up from $22.00.
• 9/15/2026 – Beta Bionics had its “buy” rating reaffirmed by UBS Group. They now have a $25.00 price target on the stock.
• 9/15/2026 – Beta Bionics had its price target raised by Bank of America from $18.00 to $20.00. They now have a “neutral” rating on the stock.
• 9/15/2026 – Beta Bionics had its price target raised by Robert W. Baird from $14.00 to $16.00. They now have a “neutral” rating on the stock.
• 9/14/2026 – Beta Bionics had its price target raised by Leerink Partners from $24.00 to $27.00. They now have an “outperform” rating on the stock.

Insider Activity at Beta Bionics

In other news, insider Mike Mensinger sold 4,375 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $83,606.25. Following the completion of the sale, the insider owned 180,040 shares of the company’s stock, valued at approximately $3,440,564.40. The trade was a 2.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Christy Jones sold 6,430 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total value of $147,890.00. Following the transaction, the director owned 19,564 shares in the company, valued at approximately $449,972. This represents a 24.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,472 shares of company stock valued at $1,920,481 in the last quarter. 5.30% of the stock is currently owned by company insiders.

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.